ArticlePloS one2014
The human antibody response to the surface of Mycobacterium tuberculosis.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection.Scientific reports · 2018Trial
- Latently and uninfected healthcare workers exposed to TB make protective antibodies againstProceedings of the National Academy of Sciences of the United States of America · 2017Trial
- Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review.Annals of medicine · 2024Review
- B Cell and Antibody Responses in Bovine Tuberculosis.Antibodies (Basel, Switzerland) · 2024Review
- Antigen specificity shapes antibody functions in tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis.Biology direct · 2024Article
- Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO molecular medicine · 2022Review
- Distinct and shared B cell responses of tuberculosis patients and their household contacts.PloS one · 2022Article
- Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.Frontiers in immunology · 2022Review
- TB or not to be: what specificities and impact do antibodies have during tuberculosis?Oxford open immunology · 2021Review
- Multipathogen Analysis of IgA and IgG Antigen Specificity for Selected Pathogens in Milk Produced by Women From Diverse Geographical Regions: The INSPIRE Study.Frontiers in immunology · 2020Article
- Article
- First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment.Vaccines · 2019Article
- Biomarkers for tuberculosis: the case for lipoarabinomannan.ERJ open research · 2019Review
- Mycobacterial mannose-capped lipoarabinomannan: a modulator bridging innate and adaptive immunity.Emerging microbes & infections · 2019Review
- Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.Frontiers in immunology · 2019Review
- Extracellular vesicles released by J774A.1 macrophages reduce the bacterial load in macrophages and in an experimental mouse model of tuberculosis.International journal of nanomedicine · 2019Article
- A polymeric immunoglobulin-antigen fusion protein strategy for enhancing vaccine immunogenicity.Plant biotechnology journal · 2018Article
- Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis.Pathogens and disease · 2018Review
- Characterising antibody avidity in individuals of varied Mycobacterium tuberculosis infection status using surface plasmon resonance.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundVaccine-induced human antibodies to surface components of Haemophilus influenzae and Streptococcus pneumonia are correlated with protection. Monoclonal antibodies to surface components of Mycobacterium tuberculosis are also protective in animal models. We have characterized human antibodies that bind to the surface of live M. tuberculosis.
methodsPlasma from humans with latent tuberculosis (TB) infection (n = 23), active TB disease (n = 40), and uninfected controls (n = 9) were assayed by ELISA for reactivity to the live M. tuberculosis surface and to inactivated M. tuberculosis fractions (whole cell lysate, lipoarabinomannan, cell wall, and secreted proteins).
resultsWhen compared to uninfected controls, patients with active TB disease had higher antibody titers to the surface of live M. tuberculosis (Δ = 0.72 log10), whole cell lysate (Δ = 0.82 log10), and secreted proteins (Δ = 0.62 log10), though there was substantial overlap between the two groups. Individuals with active disease had higher relative IgG avidity (Δ = 1.4 to 2.6) to all inactivated fractions. Surprisingly, the relative IgG avidity to the live M. tuberculosis surface was lower in the active disease group than in uninfected controls (Δ = -1.53, p = 0.004). Patients with active disease had higher IgG than IgM titers for all inactivated fractions (ratios, 2.8 to 10.1), but equal IgG and IgM titers to the live M. tuberculosis surface (ratio, 1.1). Higher antibody titers to the M. tuberculosis surface were observed in active disease patients who were BCG-vaccinated (Δ = 0.55 log10, p = 0.008), foreign-born (Δ = 0.61 log10, p = 0.004), or HIV-seronegative (Δ = 0.60 log10, p = 0.04). Higher relative IgG avidity scores to the M. tuberculosis surface were also observed in active disease patients who were BCG-vaccinated (Δ = 1.12, p < 0.001) and foreign-born (Δ = 0.87, p = 0.01). CONCLUSIONS/SIGNIFICANCE: Humans with active TB disease produce antibodies to the surface of M. tuberculosis with low avidity and with a low IgG/IgM ratio. Highly-avid IgG antibodies to the M. tuberculosis surface may be an appropriate target for future TB vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.